| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $16 price target.
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering.
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricin...